Anthony Davies on the first ever episode of Phacilitate: Talks
CEO Anthony Davies had the distinct honor of being on the panel for the inaugural episode of Phacilitate: Talks, a socially-distanced podcast for the Cell & Gene Therapy space.
…
Kelley
Davis and BioProcess Int’l: a reality check
Cell and Gene Therapies Get a Reality Check: A Conversation with Anthony Davies of Dark Horse Consulting Group
As founder of cell and gene therapy (CGT) specialist firm Dark Horse Consulting Group in California, Anthony Davies speaks from a quarter …
In testing as in life, context is everything
by Katy Spink, Dark Horse COO
Recent events in the battle to contain the global COVID-19 pandemic have me recalling one of the most memorable lessons of my graduate school education, and thinking about parallels in Cell and Gene Therapy …
Remote Virtual Audits: whitepaper and related new offering
By Robert Allen, Ph.D.
Get organised and get smart. The virtual audit: Ensuring quality and compliance during the current global pandemic Learn more about this offeringExecutive summary of Dark Horse Consulting Group’s April 2020 Whitepaper
- Current global circumstances prevent
We are doing the wrong test
This isn’t really a sentence that early 2019 me would have foreseen myself writing but, here we are. I wish to propose a new paradigm for addressing novel global pandemics: serological (blood) testing for immunity. Such a standard is proactive, …
Gene therapy is expensive. But so are misleading attacks.
by Anthony Davies
**I am aware that I’m posting this on the dawn of the American election event that is Super Tuesday, 2020. I do not intend my comments here as any sort of endorsement of any of the …
Anthony Davies considers the possibility of a new CMC norm in this BPI article
In this Feb 2020 bioprocessintl.com article (click here), Dan Stanton talks to Dark Horse CEO Anthony Davies about what pattern Catalent’s $315M acquisition of Masthercell might be foreshadowing.…
2019: the year the tools and tech C and GT gold rush began
by Katy Spink
I was born and bred in California. As an adult, I’ve been working in California’s cell & gene therapy space since long before anyone in their right mind would have used “cell & gene therapy” and “gold” …
Best practices in preclinical development of cell therapy products
By Nathan Manley & Katy Spink
The cell therapy field is currently in an exciting era of expansion, with a large number of candidate therapies advancing into clinical testing and many more progressing through preclinical pipelines. As the number of …
Zolgensma will still be the first $1B gene therapy
By Anthony Davies
Say what you will about Novartis; it’s always interesting over there by the Rhine. It’s been a rollercoaster of news about Zolgensma lately—from the timing of the data manipulation reporting…to the excellent 3Q earnings…to Japan and the …